Jeffrey Stoss - North Bud Chief Officer
Insider
Jeffrey Stoss is Chief Officer of North Bud Farms
| Phone | 855-628-3420 |
| Web | https://www.northbud.com |
Similar Executives
| Showing other executives | INSIDER Age | ||
| Sibyl Swift | cbdMD Inc | 43 | |
| Elizabeth JD | ANI Pharmaceuticals | N/A | |
| Sandra Beaver | Evolus Inc | 46 | |
| Raymond Coffman | cbdMD Inc | 62 | |
| BComm BCom | Akanda Corp | 68 | |
| Alex Dasalla | Collegium Pharmaceutical | N/A | |
| Kevin MacDermott | cbdMD Inc | 62 | |
| Thomas Flow | Akanda Corp | 46 | |
| Muthusamy RPh | ANI Pharmaceuticals | 56 | |
| John Weston | cbdMD Inc | N/A | |
| CCFP DipSportMed | Evolus Inc | 60 | |
| Rami Levy | INC Research Holdings | 59 | |
| Tejinder Virk | Akanda Corp | 42 | |
| Scott Sudduth | Collegium Pharmaceutical | N/A | |
| David Erickson | Evolus Inc | N/A | |
| Eugene III | Biofrontera | 39 | |
| Amos Cohen | INC Research Holdings | 45 | |
| Marlo Manning | Collegium Pharmaceutical | N/A | |
| BCom BAcc | Akanda Corp | 44 | |
| Matthew Coapman | cbdMD Inc | 48 | |
| Erica CPA | Biofrontera | 39 | |
North Bud Farms Leadership Team
Elected by the shareholders, the North Bud's board of directors comprises two types of representatives: North Bud inside directors who are chosen from within the company, and outside directors, selected externally and held independent of North. The board's role is to monitor North Bud's management team and ensure that shareholders' interests are well served. North Bud's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, North Bud's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward Miller, VP Communications | ||
| Peter Souchen, Chief Officer | ||
| Jeffrey Stoss, Chief Officer | ||
| Kyle Foley, Head Management | ||
| Magda Farid, VP Compliance | ||
| Ryan Brown, Interim Chairman | ||
| Kosta LLB, Sec |
North Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is North Bud a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 1.07 M | |||
| Shares Outstanding | 63.44 M | |||
| Price To Book | 0.35 X | |||
| Net Income | (1.8 M) | |||
| Cash And Equivalents | 1.46 M | |||
| Cash Per Share | 0.02 X | |||
| Current Ratio | 2.10 X | |||
| Book Value Per Share | 0.13 X | |||
| Cash Flow From Operations | (357.49 K) | |||
| Earnings Per Share | (0.03) X |
Currently Active Assets on Macroaxis
Other Information on Investing in North Pink Sheet
North Bud financial ratios help investors to determine whether North Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in North with respect to the benefits of owning North Bud security.